{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:46:57Z","timestamp":1792424817759,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012735","name":"Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research: Neuroimaging"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.pscychresns.2022.111515","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T21:36:41Z","timestamp":1655933801000},"page":"111515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study"],"prefix":"10.1016","volume":"325","author":[{"given":"Yvonne S.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Maddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huailin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Hellemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pscychresns.2022.111515_bib0001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jmri.21832","article-title":"Measurement of glutathione in normal volunteers and stroke patients at 3T using J-difference spectroscopy with minimized subtraction errors","volume":"30","author":"An","year":"2009","journal-title":"J. Magn. Reson. Imaging\u00a0: JMRI"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0002","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/ijms18030651","article-title":"Neuroinflammation and oxidative stress in psychosis and psychosis risk","volume":"18","author":"Barron","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2013a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0004","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.tips.2013.01.001","article-title":"The promise of N-acetylcysteine in neuropsychiatry","volume":"34","author":"Berk","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","article-title":"Multiple significance tests: the Bonferroni method","volume":"310","author":"Bland","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2018.03.012","article-title":"Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders","volume":"199","author":"Breier","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jcph.1008","article-title":"Repeated-dose oral N-Acetylcysteine in Parkinson&Apos;s disease: pharmacokinetics and effect on brain glutathione and oxidative stress","volume":"58","author":"Coles","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0008","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/schbul\/sbx093","article-title":"N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis","volume":"44","author":"Conus","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0009","first-page":"0","article-title":"Antioxidant defense in schizophrenia and bipolar disorder_ A meta-analysis of MRS studies of anterior cingulate glutathione","author":"Das","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2019.06.003","article-title":"Markers of glutamate and GABA neurotransmission in the prefrontal cortex of schizophrenia subjects: disease effects differ across anatomical levels of resolution","volume":"217","author":"Dienel","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0011","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","article-title":"Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo","volume":"12","author":"Do","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mrm.1910360320","article-title":"Elimination of artifacts in short echo time H MR spectroscopy of the frontal lobe","volume":"36","author":"Ernst","year":"1996","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.psychres.2019.03.018","article-title":"Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: a pilot in vivo proton magnetic resonance spectroscopy study","volume":"275","author":"Girgis","year":"2019","journal-title":"Psychiat. Res."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0014","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.schres.2011.06.030","article-title":"Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS)","volume":"132","author":"Horan","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0016","first-page":"10","article-title":"Glutathione and glutamate in schizophrenia: a 7T MRS study","volume":"38","author":"Kumar","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0017","first-page":"189","article-title":"Extracellular free water and glutathione in first-episode psychosis-a multimodal investigation of an inflammatory model for psychosis","volume":"45","author":"Lesh","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0018","doi-asserted-by":"crossref","first-page":"e4484","DOI":"10.1002\/nbm.4484","article-title":"Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts\u2019 consensus recommendations","volume":"34","author":"Lin","year":"2021","journal-title":"NMR Biomed."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0020","doi-asserted-by":"crossref","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","article-title":"Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study","volume":"3","author":"Matsuzawa","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0021","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00213-018-4997-2","article-title":"Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia","volume":"235","author":"McQueen","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0022","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J","article-title":"Simultaneous in vivo spectral editing and water suppression","volume":"11","author":"Mescher","year":"1998","journal-title":"NMR Biomed."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology\u00a0: official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0025","doi-asserted-by":"crossref","first-page":"17365","DOI":"10.1523\/JNEUROSCI.2904-12.2012","article-title":"Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset","volume":"32","author":"Pasternak","year":"2012","journal-title":"The Journal of neuroscience\u00a0: the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0026","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.schres.2017.07.008","article-title":"Treatment in early psychosis with N-acetyl-cysteine for 6months improves low-level auditory processing: pilot study","volume":"191","author":"Retsa","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0027","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1016\/j.bbagen.2013.04.016","article-title":"The chemistry and biological activities of N-acetylcysteine","volume":"1830","author":"Samuni","year":"2013","journal-title":"BBA - General Subjects"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0028","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/npp.2012.66","article-title":"N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study","volume":"37","author":"Schmaal","year":"2012","journal-title":"Neuropsychopharmacology\u00a0: official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0029","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0891-5849(99)00177-X","article-title":"Glutathione and its role in cellular functions","volume":"27","author":"Sies","year":"1999","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fncel.2013.00031","article-title":"NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia","volume":"7","author":"Snyder","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.schres.2020.06.028","article-title":"A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: implications for studies of psychosis risk","volume":"226","author":"Sydnor","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mrm.10499","article-title":"Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra","volume":"50","author":"Terpstra","year":"2003","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0033","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13229-016-0088-6","article-title":"A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder","volume":"7","author":"Wink","year":"2016","journal-title":"Mol Autism"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0034","doi-asserted-by":"crossref","first-page":"e12900","DOI":"10.1111\/adb.12900","article-title":"N-acetylcysteine reduces cocaine-seeking behavior and anterior cingulate glutamate\/glutamine levels among cocaine-dependent individuals","volume":"26","author":"Woodcock","year":"2021","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0035","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/schbul\/sbw038","article-title":"Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis","volume":"42","author":"Xin","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2019.01.036","article-title":"N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: a randomized, controlled pilot study","author":"Yang","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pscychresns.2022.111515_bib0037","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/neu.2019.29","article-title":"Brain glutathione levels and age at onset of illness in chronic schizophrenia","volume":"31","author":"Yang","year":"2019","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","article-title":"Altered Glutathione Redox State in Schizophrenia","volume":"22","author":"Yao","year":"2006","journal-title":"Dis. Markers"},{"key":"10.1016\/j.pscychresns.2022.111515_bib0039","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0004867419893439","article-title":"Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia","volume":"54","author":"Yolland","year":"2020","journal-title":"Australian New Zealand J. Psychiatry"}],"container-title":["Psychiatry Research: Neuroimaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925492722000762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925492722000762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:39:10Z","timestamp":1760420350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925492722000762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"alternative-id":["S0925492722000762"],"URL":"https:\/\/doi.org\/10.1016\/j.pscychresns.2022.111515","relation":{},"ISSN":["0925-4927"],"issn-type":[{"value":"0925-4927","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research: Neuroimaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscychresns.2022.111515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111515"}}